Schering-Plough to reveal boceprevir trial outcome

Schering-Plough has revealed that it will present the findings of a study into its investigational hepatitis C virus (HCV) protease inhibitor boceprevir at a liver disease conference taking place between October 30th and November 3rd 2009.

The firm plans to detail the sustained virologic response (SVR) results on boceprevir triple combination therapy in treatment-naive HCV genotype 1 patients who had a null response to peginterferon and ribavirin

This group is generally considered to be the most difficult to treat.

A planned presentation will also relate the outcome of studies into Pegintron (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy, an approved treatment regimen for chronic hepatitis C.

Earlier this week, Schering-Plough’s human vaccine division Nobilon announced the start of a clinical proof of concept trial into SCH 900795, a new intranasal live attenuated influenza vaccine (LAIV) for annual seasonal use.

Unlike other influenza vaccines, LAIV offers single-dose intranasal delivery and advanced-cell culture manufacturing technology.